See the latest news and media coverage for Klaria. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pharmaceutical developer using alginate film technology
klaria.comLast updated
In short: Klaria partnered with RTHS for migraine detection, proposed a 148 million SEK rights issue, and reported its 2026 financial results.
The collaboration combines the EU-approved Sumatriptan Alginate Film with non-invasive blood flow sensors. This integration enables personalized interventions before full attacks occur.
Shareholders will vote on raising up to SEK 147 million through a rights issue and amending the articles of association.
The European Patent Office will grant the second patent in full, broadening protection in major markets and allowing flexibility in manufacturing and infringement enforcement.
The meeting adopted 2025 financials, re-elected board members, and authorized a 20% share capital increase.
Klaria Pharma Holding AB has published its financial results for the second quarter and the half-year ended June 30, 2026. For the second quarter...
The pharmaceutical company Klaria Pharma intends to make a rights issue of approximately 148 million kronor, with the aim of strengthening the company's financial position...
1 Day KLAR 5.08% DJIA 0.98% Russell 2K 0.85% Health Care/Life Sciences 1.08% ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
Track Klaria and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Klaria and other trending companies.